SOURCE: Atossa Genetics, Inc.

Atossa Genetics, Inc.

November 14, 2012 15:30 ET

Atossa Genetics, Inc. Announces Closing of Initial Public Offering

SEATTLE, WA--(Marketwire - Nov 14, 2012) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today the closing of its initial public offering of 800,000 shares of its common stock at an initial public offering price of $5.00 per share. Atossa Genetics' common stock is traded on the NASDAQ Capital Market under the trading symbol "ATOS."

Dawson James Securities, Inc. acted as the sole book-running manager and lead underwriter for this offering along with ViewTrade Securities, Inc. and Paulson Investment Company.

A copy of the final prospectus relating to the offering may be obtained by contacting Monique Maclaren of Dawson James Securities, Inc. at (561) 391-5555 or by emailing or by standard mail at 925 S. Federal Highway, Suite 600, Boca Raton, FL 33432. You may also obtain these documents for free by visiting EDGAR on the SEC's website at

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 7, 2012. This offering was made solely by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Atossa Genetics, Inc.

Atossa Genetics, Inc., The Breast Health Company, is based in Seattle, Washington, and is focused on the prevention of breast cancer through the commercialization of diagnostic medical devices and tests that can detect precursors to breast cancer, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

Contact Information

  • Contact:

    Atossa Genetics, Inc.
    Steven C. Quay, M.D., Ph.D., FCAP
    Chairman, President and CEO of Atossa Genetics and
    Director of the National Reference Laboratory for Breast Health
    Email Contact

    Matthew D. Haines (Investors and Media)
    Managing Director
    MBS Value Partners
    Email Contact